Literature DB >> 9972677

Evaluation of growth hormone bioactivity using the Nb2 cell bioassay in children with growth disorders.

M Bozzola1, M Zecca, F Locatelli, G Radetti, S Pagani, M Autelli, L Tatò, P Chatelain.   

Abstract

The Nb2 cell bioassay could be a useful tool for evaluating human growth hormone (hGH) bioactivity, but is not specific for hGH since it relies on the ability of the hormone to produce effects by cross-reacting with the lactogenic receptor on Nb2 cells. We studied the biological activity of both endogenous and exogenous hGH in short patients using the Nb2 bioassay after inhibiting the mitogenic effect of the other lactogenic hormone, that is human prolactin (hPRL), by adding a specific antibody against hPRL to each assay. The in vitro study showed a significant (p<0.0001) increase in Nb2 cell proliferation when increasing concentrations of highly purified hGH were added to the cell culture. A complete inhibition of Nb2 cell replication was observed after adding a specific antibody against hGH. The in vivo study showed a significantly (p<0.0001) lower hGH bioactivity (4.90+/-0.28 ng/ml) evaluated during stimulation tests in 9 children with total idiopathic GH deficiency, mean age 9.25+/-1.99 years, in comparison with that found in 11 short children with normal growth velocity, mean age 8.22+/-1.41 years (12.25+/-1.19 ng/ml). Likewise, serum GH levels measured by immunofluorometric assay IFMA in the same serum samples were significantly (p<0.001) lower in the 9 GH-deficient (1.97+/-0.37 ng/ml) than in the 11 short children (21.85+/-2.71 ng/ml). Moreover, we evaluated GH concentrations using both IFMA and the Nb2 cell bioassay in serum samples collected from another 11 idiopathic GH-deficient children, mean age 10.71+/-1.18 years, before and then, 6 and 24 hours following the 1 st injection of r-hGH (0.1 IU/kg sc). Serum GH values measured by both IFMA and Nb2 bioassay significantly (p<0.0001) increased 6 hours after r-hGH administration and decreased to reach basal levels after 24 hours. In conclusion, the Nb2 cell bioassay with minor modifications seems to provide a specific and sensitive assessment of hGH bioactivity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9972677     DOI: 10.1007/bf03348043

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  21 in total

Review 1.  Receptor assays for growth hormone.

Authors:  H G Friesen
Journal:  Acta Paediatr Scand Suppl       Date:  1990

2.  Assay of growth hormone levels in human plasma using commercial kits: analysis of some factors influencing the results.

Authors:  P Chatelain; B Bouillat; R Cohen; G Sassolas; J C Souberbielle; A Ruitton; M O Joly; J C Job
Journal:  Acta Paediatr Scand Suppl       Date:  1990

3.  Assay-dependent results of immunoassayable spontaneous 24-hour growth hormone secretion in short children.

Authors:  M L Granada; A Sanmartí; A Lucas; I Salinas; A Carrascosa; M Foz; L Audí
Journal:  Acta Paediatr Scand Suppl       Date:  1990

Review 4.  Growth hormone binding proteins and various forms of growth hormone: implications for measurements.

Authors:  G Baumann
Journal:  Acta Paediatr Scand Suppl       Date:  1990

Review 5.  Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins.

Authors:  G Baumann
Journal:  Endocr Rev       Date:  1991-11       Impact factor: 19.871

Review 6.  Accuracy of growth hormone measurements.

Authors:  S Woodhead; G Turner
Journal:  Horm Res       Date:  1991

7.  Reactivity of non-primate growth hormones and prolactins with human growth hormone receptors on cultured human lymphocytes.

Authors:  M A Lesniak; P Gorden; J Roth
Journal:  J Clin Endocrinol Metab       Date:  1977-05       Impact factor: 5.958

8.  Rational design of receptor-specific variants of human growth hormone.

Authors:  B C Cunningham; J A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

9.  Zinc mediation of the binding of human growth hormone to the human prolactin receptor.

Authors:  B C Cunningham; S Bass; G Fuh; J A Wells
Journal:  Science       Date:  1990-12-21       Impact factor: 47.728

Review 10.  Metabolism of growth hormone (GH) and different molecular forms of GH in biological fluids.

Authors:  G Baumann
Journal:  Horm Res       Date:  1991
View more
  6 in total

1.  The level of bioavailable growth hormone (GH) after the first GH injection predicts the first year's growth response in GH-deficient children.

Authors:  M Bozzola; G Radetti; S Pagani; M Draghi; G Aimaretti; G Rondini
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

2.  Growth hormone bioactivity and immunoactivity in tall children.

Authors:  M Bozzola; G Radetti; F Buzi; G Tonini; A Moretta; M Autelli; A Aglialoro; G Rondini; A Barreca
Journal:  J Endocrinol Invest       Date:  1999 Jul-Aug       Impact factor: 4.256

3.  Efficacy of long-term growth hormone therapy in short children with reduced growth hormone biological activity.

Authors:  S Pagani; C Meazza; K Laarej; F Cantoni; M Bozzola
Journal:  J Endocrinol Invest       Date:  2011-04-20       Impact factor: 4.256

4.  Functional human antibody CDR fusions as long-acting therapeutic endocrine agonists.

Authors:  Tao Liu; Yong Zhang; Yan Liu; Ying Wang; Haiqun Jia; Mingchao Kang; Xiaozhou Luo; Dawna Caballero; Jose Gonzalez; Lance Sherwood; Vanessa Nunez; Danling Wang; Ashley Woods; Peter G Schultz; Feng Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-20       Impact factor: 11.205

5.  Dose dependency of the serum bio/immuno GH ratio in children during pharmacological secretion tests.

Authors:  E A Chaler; P Travaglino; S Pagani; E Bozzola; R Marino; E Berensztein; M Maceiras; M Tauber; M A Rivarola; A Belgorosky; M Bozzola
Journal:  J Endocrinol Invest       Date:  2006-02       Impact factor: 4.256

6.  Growth hormone isoforms release in response to physiological and pharmacological stimuli.

Authors:  S Pagani; M Cappa; C Meazza; G Ubertini; P Travaglino; E Bozzola; M Bozzola
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.